Marco Meglio

Over a 2-year period, patients demonstrated improvements in Parkinson’s Disease Questionnaire scores, along with a 35% improvement in MDS-UPDRS-III scores.

Treatment with NurOwn resulted in response on several secondary outcomes, including timed 25-foot walk, 12-item multiple sclerosis walking scale, and low contrast letter acuity, among others.

Approximately half of the respondents with a history of headache screened positive for migrainous headache by ID-migraine criterion with most reporting moderate to severe intensity headache.

In addition to headache, other COVID-19 symptoms such as anosmia, myalgia, and nausea or vomiting were associated with higher survival rates.

Patients who demonstrated increased central pulse pressure and forward wave amplitude had greater entorhinal tau burden. These measures were not associated with amygdala, inferior temporal, nor precuneus tau burden.

Long-term use of the Constant Therapy program was feasible in a patient population with Alzheimer disease, as shown by the rate of adherence (80%) and use of the program over 24 weeks.

The molecular biologist at the Cleveland Clinic Lerner Research Institute discussed the unanswered questions regarding biomarkers sTREM2 and GFAP, and the role they play in Alzheimer pathology.

In a previous phase 2 study, patients treated with fosgonimeton alone demonstrated potentially beneficial change in ERP P300 latency, as well as cognitive improvement, compared with placebo at 26 weeks.

Infudopa SubC, or subcutaneous DIZ102, demonstrated 100% bioavailability compared with 80% for intestinal administration of levodopa/carbidopa gel infusion.

A doubling of mean seizure intervals was demonstrated from period 1 to period 4 for the 76-patient cohort who received the Neurelis nasal spray treatment across 360 days.

Jay Alberts, PhD, the Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic, provided commentary on an innovative approach using virtual reality to detect early signs of Parkinson disease.

Using patients with post–COVID-19 neurological symptoms, 90% of the cohort fulfilled the criteria for chronic fatigue syndrome, as expressed by the SOFA scale.

If approved, the oral fixed-dose coformulation of sodium phenylbutyrate-taurursodiol will become the third medication to receive an FDA greenlight for ALS.

In a recently submitted medical device report, Philips reported 14 serious injuries and 0 deaths related to the use of the recalled masks.

The substudy of the COVER-MS Project includes 300 patients with multiple sclerosis and will harness Quest Diagnostic’s national network of more than 2100 patient centers to provide periodic blood samples of immune responses to COVID-19 vaccines.

The molecular biologist at the Cleveland Clinic Lerner Research Institute provided commentary on how certain activity markers may help understand immune response differences in Alzheimer disease and related dementias.

Despite efforts to reduce perioperative complications rates by vetting of surgeons and sites, and refining patient selection, the findings nonetheless demonstrated no clinical benefit from the addition of stenting to medical therapy.

Stringent governmental measures predicted lower global scores on Pittsburgh Sleep Quality Index, while, albeit to a small extent, less restrictive measures were related to worse subjective sleep quality.

Among controls, there was a statistically significant difference of modified Rankin Scale scores between patients with and without atrial fibrillation, whereas no statistical difference was observed in the implantable loop recorder group.

Treatment with rimegepant, an FDA-approved treatment for acute and preventative migraine, resulted in decreases of more than 30% in monthly butalbital prescription fill and reductions of more than 25% in mean milligrams dispensed.

Compared with placebo, vamorolone-treated patients showed significantly better outcomes on several secondary and exploratory end points, such as the NorthStar Ambulatory Assessment and time to climb 4 stairs.

Evening physical activity was associated with lower restless legs syndrome severity, while more time spent in the morning on physical activity, specifically light physical activity, was associated with worse sleep quality.

Using Strong et al’s classification criteria, the percentage of SOD1+ and SOD1- patients with altered cognitive and/or behavioral profiles were similar; however, cognitive and behavioral impairment differentiated between groups.

After switching from idursulfase to Denali’s DNL310, patients demonstrated mean declines of more than 80% for both heparan sulfate and dermatan sulfate biomarkers at week 49 of treatment.

Milvexian at doses of 25 mg to 100 mg twice daily showed an approximate 30% relative risk reduction of ischemic stroke compared with placebo.

Even after adjusting for multiple confounding variables including recognized factors associated with cardiovascular diseases, PTSD plus insomnia remained an independent factor of major adverse cardiovascular events.

In comparison to nonresponders, those in the active treatment group who did respond well exhibited longer disease duration and lower baseline levodopa equivalent dose.

The director of medical outpatient services at the Kennedy Krieger Institute discussed the changes and implications of new CDC guidelines on developmental milestones for growing children.

Younger patients were more likely to have epilepsy-related imaging abnormalities, while older patients were more likely to have incidental abnormalities or those with an unknown relationship to epilepsy.

In a subanalysis of individuals with acute ischemic stroke with tandem lesions, treatment with the Penumbra system resulted in successful revascularization in almost 90% of patients.